'Enough is enough': Khar residents protest over pub noise, traffic chaos and safety concerns

Around 150 Khar residents protested over pub-related noise, traffic chaos and safety concerns, seeking stricter action from ...
Hindustan Times

‘Enough is enough’: Khar residents protest pub nuisance

MUMBAI: When Bhavika, 27, returns from work late at night, she doesn’t walk straight to her building. Instead, she phones her brother and asks him to meet her at the gate. “This is how unsafe it has ...
CBC뉴스

일라이릴리 ‘제이피르카’, 미 FDA 1차 치료 적응증 확대…CLL·SLL 치료 범위 넓혀

[CBC뉴스] 일라이릴리의 혈액암 치료제 제이피르카(성분명 피르토브루티닙)가 미국에서 만성 림프구성 백혈병과 소림프구성 림프종의 초기 치료 영역까지 사용 범위를 넓혔다.일라이릴리는 미국 식품의약국(FDA)이 제이피르카의 추가 ...
kndaily.co.kr

릴리 제이피르카, FDA서 미치료 CLL·SLL 1차 치료 적응증 추가

기사의 본문 내용은 이 글자크기로 변경됩니다. 미국 식품의약국(FDA)은 릴리 사의 제이피르카(Jaypirca)를 만성 림프구성 백혈병/소림프구성 백혈병(CLL/SLL)의 1차 치료제로 승인했다. (다렌 인코르바이야) ...
Press Trust of India on MSN

Asian Masters Swimming c’ships to be held in Bengaluru from October 4-10

Bengaluru, Oct 3 (PTI) More than 1,500 swimmers are set to take part in the second edition of the Asian Masters Swimming Championships to be held here from Sunday ...
RTTNews

FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL

The approval allows Jaypirca to be used as a first-line treatment for eligible patients. Jaypirca is the first and only FDA-approved non-covalent Bruton tyrosine kinase (BTK) inhibitor and is designed ...
oncodailyOpinion

Kavya Keerthana: A New Development in CLL Treatment: Pirtobrutinib Moves Into the Frontline

“A new development in CLL treatment: Pirtobrutinib moves into the frontline. On October 2, 2026, the US FDA approved ...